Free tool
FAERS Monitor: Rezenopy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215487 or its brand name (Rezenopy, Naloxone Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
809
Serious
510
63% of reports
Hospitalization
284
Death reported
100
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue90
- nausea73
- headache54
- drug ineffective52
- diarrhoea51
- off label use50
- pain50
- death47
- dyspnoea47
- product dose omission issue46
- asthenia37
- rash36
- decreased appetite34
- pneumonia33
- arthralgia32
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 6 |
| 2011 | 5 |
| 2012 | 15 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 10 |
| 2017 | 19 |
| 2018 | 35 |
| 2019 | 41 |
| 2020 | 49 |
| 2021 | 28 |
| 2022 | 58 |
| 2023 | 120 |
| 2024 | 128 |
| 2025 | 157 |
| 2026 | 119 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,350 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product dose omission issueSignal | 46 | 4.1 | 3.1 | 105 |
| decreased appetiteSignal | 34 | 3.8 | 2.7 | 68 |
| fatigueSignal | 90 | 3.0 | 2.5 | 123 |
| pneumoniaSignal | 33 | 2.7 | 1.9 | 33 |
| astheniaSignal | 37 | 2.6 | 1.9 | 34 |
| nauseaSignal | 73 | 2.4 | 1.9 | 60 |
| headacheSignal | 54 | 2.2 | 1.7 | 37 |
| dyspnoeaSignal | 47 | 2.2 | 1.6 | 29 |
| rashSignal | 36 | 2.1 | 1.6 | 21 |
| painSignal | 50 | 2.1 | 1.6 | 29 |
| diarrhoeaSignal | 51 | 2.1 | 1.6 | 27 |
| arthralgiaSignal | 32 | 2.0 | 1.4 | 15 |
| off label use | 50 | 1.5 | 1.1 | 8 |
| death | 47 | 1.4 | 1.1 | 6 |
| drug ineffective | 52 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.